Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2007 1
2013 1
2014 2
2015 7
2016 9
2017 11
2018 8
2019 8
2020 4
2021 5
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Collagen triple helix repeat-containing protein 1 is a novel biomarker of right ventricular involvement in pulmonary hypertension.
Yokokawa T, Nishiura K, Katahira M, Sato Y, Miura S, Sato A, Shimizu T, Misaka T, Sato T, Kaneshiro T, Oikawa M, Yoshihisa A, Sugimoto K, Fukushima K, Nakazato K, Takeishi Y. Yokokawa T, et al. Among authors: miura s. Can J Cardiol. 2024 Apr 29:S0828-282X(24)00337-4. doi: 10.1016/j.cjca.2024.04.016. Online ahead of print. Can J Cardiol. 2024. PMID: 38692430
Prognostic Role of Circulating LTBP-2 in Patients With Dilated Cardiomyopathy: A Novel Biomarker Reflecting Extracellular Matrix LTBP-2 Accumulation.
Nishiura K, Yokokawa T, Misaka T, Ichimura S, Tomita Y, Miura S, Shimizu T, Sato T, Kaneshiro T, Oikawa M, Kobayashi A, Yoshihisa A, Takeishi Y. Nishiura K, et al. Among authors: miura s. Can J Cardiol. 2023 Oct;39(10):1436-1445. doi: 10.1016/j.cjca.2023.05.015. Epub 2023 Jun 2. Can J Cardiol. 2023. PMID: 37270166
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S. Ebata S, et al. Among authors: miura s. Lancet Rheumatol. 2022 Aug;4(8):e546-e555. doi: 10.1016/S2665-9913(22)00131-X. Epub 2022 Jun 28. Lancet Rheumatol. 2022. PMID: 38294008 Clinical Trial.
Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Yoshihide A, Yoshizaki A, Sato S. Ebata S, et al. Among authors: miura s. Rheumatology (Oxford). 2022 Nov 2;61(11):4364-4373. doi: 10.1093/rheumatology/keac023. Rheumatology (Oxford). 2022. PMID: 35136981 Clinical Trial.
Anaphylaxis to lipid transfer protein from butterbur scape.
Miura S, Moriyama T, Yoshimura J, Umehara K, Hino H, Tsunoda T, Kagami S. Miura S, et al. J Dermatol. 2022 Jan;49(1):e36-e37. doi: 10.1111/1346-8138.16213. Epub 2021 Oct 29. J Dermatol. 2022. PMID: 34713925 No abstract available.
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.
Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S. Ebata S, et al. Among authors: miura s. Lancet Rheumatol. 2021 Jul;3(7):e489-e497. doi: 10.1016/S2665-9913(21)00107-7. Epub 2021 May 26. Lancet Rheumatol. 2021. PMID: 38279402
57 results